Wan Wook Kim

Wan Wook Kim

Auto-generated profile, based on publicly available information

Wan Wook Kim

Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
PHPatricia Aragon Han
Patricia Aragon Han
MOMatthew T. Olson
Matthew T. Olson
RFRoghayeh Fazeli
Roghayeh Fazeli
JPJason D. Prescott
Jason D. Prescott
SPSara I. Pai
Sara I. Pai
MZMartha A. Zeiger
Martha A. Zeiger

5 September 2018 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
WKWan Wook Kim
Wan Wook Kim
JLJeeyeon Lee
Jeeyeon Lee
JJJin Hyang Jung
Jin Hyang Jung
HPHo Yong Park
Ho Yong Park
RTRalph P. Tufano
Ralph P. Tufano
HKHoon Yub Kim
Hoon Yub Kim

26 March 2014 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
SHSeung Ook Hwang
Seung Ook Hwang
JJJin Hyang Jung
Jin Hyang Jung
HPHo Yong Park
Ho Yong Park
WKWan Wook Kim
Wan Wook Kim

30 August 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
WKWon Hwa Kim
Won Hwa Kim
HKHye Jung Kim
Hye Jung Kim
SKSee Hyung Kim
See Hyung Kim
JJJin Hyang Jung
Jin Hyang Jung
HPHo Yong Park
Ho Yong Park
SLSOO JUNG LEE
SOO JUNG LEE
We report on our experience of ultrasound (US)-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy (NAC) with clip and activated charcoal to guide axillary surgery in breast cancer patients. Between November 2017 and May 2018, a dual-localization procedure was performed under US guidance for the most suspicious axillary nodes noted at initial staging (before NAC, with clip) and restaging (after NAC, with activated charcoal) in 28 cytologically proven node-positive breast cancer patients. Patients underwent axillary sampling or dissection, which involved removing not only the sentinel nodes (SNs), but also clipped nodes (CNs) and tattooed nodes (TNs). Success (or failure) rates of biopsies of SNs, CNs, and TNs and inter-nodal concordance rates were determined. Sensitivities for the individual and combined biopsies were calculated. SN biopsy failed in four patients (14%), whereas the CN biopsy failed in one patient (4%). All TNs were identified in the surgical field. Concordance rates were 79% for CNs–TNs, 63% for CNs–SNs, and 58% for TNs–SNs. Sensitivity for SN, CN, and TN biopsy was 73%, 67%, and 67%, respectively. Sensitivity was 80% for any combination of biopsies (SN plus CN, SN plus TN, SN plus CN plus TN). US-guided dual-localization of axillary nodes before and after NAC with clip and activated charcoal was a feasible approach that might facilitate more reliable nodal staging with less-invasive strategies in node-positive breast cancer patients.

1 November 2018 in Journal of Surgical Research
Verified
Journal Article
Closed access
WKWan Wook Kim
Wan Wook Kim
JCJin Ah Choi
Jin Ah Choi
JLJeeyeon Lee
Jeeyeon Lee
JJJin Hyang Jung
Jin Hyang Jung
HPHo Yong Park
Ho Yong Park

25 August 2023 in Medicine
Verified
Journal Article
Open access
BKbyeongju kang
byeongju kang
JLJeeyeon Lee
Jeeyeon Lee
JJJin Hyang Jung
Jin Hyang Jung
WKWan Wook Kim
Wan Wook Kim
HKHeejung Keum
Heejung Keum
HPHo Yong Park
Ho Yong Park
The clinical features and prognosis of breast cancer can vary widely, depending on the molecular subtype. Luminal B breast cancers are usually either estrogen receptor-positive and/or progesterone receptor-positive with high proliferation of Ki67 index, or HER2 positive (HER2+). The authors compared the clinicopathologic factors and survival rates of different subtypes of luminal B breast cancer according to HER2 status. Between 2009 and 2013, 1131 cases of breast cancer were reviewed and characterized as 1 of 4 different molecular subtypes based on their immunohistochemical results: luminal A, luminal B, HER2+, or triple-negative breast cancer. From these, luminal B breast cancers were extracted and the clinical features and prognosis of the HER2- and the HER2 + subtypes were compared. Survival differed significantly based on the molecular subtype regardless of whether or not the patient received treatment with neoadjuvant chemotherapy. While patients with HER2- luminal B breast cancer who received neoadjuvant chemotherapy had better prognoses, patients with HER2 + luminal B breast cancer who did not receive neoadjuvant chemotherapy had better prognoses. Luminal B breast cancers showed different clinical outcomes and survival rates according to HER2 gene overexpression type. Physicians should consider these results when they establish a treatment strategy.